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A B S T R A C T
Background
Long-acting bronchodilators comprising long-acting beta2-agonists and the anticholinergic agent tiotropium are commonly used, either
on their own or in combination, for managing persistent symptoms of chronic obstructive pulmonary disease. Patients with severe
chronic obstructive pulmonary disease who are symptomatic and who suffer repeated exacerbations are recommended to add inhaled
corticosteroids to their bronchodilator treatment. However, the benefits and risks of adding inhaled corticosteroid to tiotropium and
long-acting beta2-agonists for the treatment of chronic obstructive pulmonary disease are unclear.
Objectives
To assess the relative effects of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists treatment in patients with
chronic obstructive pulmonary disease.
Search methods
We searched the Cochrane Airways Group Specialised Register of trials (February 2011) and reference lists of articles.
Selection criteria
We included parallel group, randomised controlled trials of three months or longer comparing inhaled corticosteroid and long-acting
beta2-agonist combination therapy in addition to inhaled tiotropium against tiotropium and long-acting beta2-agonist treatment for
patients with chronic obstructive pulmonary disease (COPD).
Data collection and analysis
Two review authors independently assessed trials for inclusion and then extracted data on trial quality and the outcome results. We
contacted study authors for additional information. We collected information on adverse effects from the trials.
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Main results
One trial (293 patients) was identified comparing tiotropium in addition to inhaled corticosteroid and long-acting beta2-agonist
combination therapy to tiotropium plus long-acting beta2-agonist. The study was of good methodological quality, however it suffered
from high and uneven withdrawal rates between the treatment arms. There is currently insufficient evidence to know how much
difference the addition of inhaled corticosteroids makes to people who are taking tiotropium and a long-acting beta2-agonist for COPD.
Authors’ conclusions
The relative efficacy and safety of adding inhaled corticosteroid to tiotropium and a long-acting beta2-agonist for chronic obstructive
pulmonary disease patients remains uncertain and additional trials are required to answer this question.
P L A I N L A N G U A G E S U M M A R Y
The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for managing chronic obstructive
pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a lung disease which includes the conditions chronic bronchitis and emphysema.
COPD is characterised by blockage or narrowing of the airways. The symptoms include breathlessness and a chronic cough. COPD
is an irreversible disease that is usually brought on by airway irritants, such as smoking or inhaled dust.
Long-acting beta2-agonists and tiotropium are two types of inhaled medications that help widen the airways (bronchodilators) for up to
12 to 24 hours. These bronchodilators are commonly used tomanage persistent symptoms of COPD. They can be used in combination
or on their own. Patients with severe COPD who suffer ongoing worsening of symptoms are recommended to add anti-inflammatory
inhaled corticosteroids to their bronchodilator treatment. However, the benefits and risks of adding inhaled corticosteroid to tiotropium
and long-acting beta2-agonists for the treatment of COPD are unclear.
This review found one study, involving 293 patients, comparing the long-term efficacy and side effects of combining inhaled corticos-
teroid with tiotropium and a long-acting beta2-agonist. In this study there were not enough patients for us to be able to draw any firm
conclusions as to whether combining inhaled corticosteroid with tiotropium and the long-acting beta2-agonist is better or worse than
using only tiotropium and the long-acting beta2-agonist. More long-term studies need to be done in order to better understand the
effect of treatment with inhaled corticosteroid, tiotropium and a long-acting beta2-agonist.
B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is a respiratory
disease characterised by chronic and progressive breathlessness,
cough, sputum production, and airflow obstruction, which leads
to restricted activity and poor quality of life (GOLD). COPD
comprises a combination of bronchitis and emphysema and in-
volves chronic inflammation and structural changes in the lung.
Cigarette smoking is the most important risk factor, however air
pollution and occupational dust and chemicals are also recog-
nised risk factors. The World Health Organization (WHO) has
estimated that COPD is the fourth or fifth most common sin-
gle cause of death worldwide and the treatment and management
costs present a significant burden to public health. Furthermore,
because of the slow onset and the under-recognition of the disease,
it is heavily under-diagnosed (GOLD). COPD is a progressive
disease leading to decreased lung function over time, even with the
best available care. There is currently no cure for COPD though
it is both a preventable and treatable disease. As yet, apart from
smoking cessation and non-pharmacological treatments such as
long-term oxygen therapy in hypoxic patients, no intervention has
been shown to reduce mortality (GOLD). Management of the
disease is multifaceted and includes reducing risk factors (van der
Meer 2001), pharmacological treatments (GOLD; NICE 2010),
education (Effing 2007) and pulmonary rehabilitation (Lacasse
2006). Pharmacological therapy is aimed at relieving symptoms,
improving exercise tolerance and quality of life, improving lung
function, or preventing and treating exacerbations. COPD exac-
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erbations impair patients’ quality of life (GOLD). Furthermore, a
large part of the economic burden of COPD is attributed to the
cost of managing exacerbations, particularly those resulting in use
of acute care services or hospitalisations (Hutchinson 2010). Ap-
propriate pharmacological management of the disease is therefore
important to reduce and prevent exacerbations.
Description of interventions
COPD pharmacological management tends to begin with one
treatment and additional therapies are introduced, as necessary, to
control symptoms (GOLD). The first step is often a short-acting
bronchodilator for control of breathlessness, when needed: either a
short-acting beta2-agonist (SABA) or the short-acting anticholin-
ergic ipratropium. For persistent or worsening breathlessness as-
sociated with lung function decline long-acting bronchodilators
may be introduced (GOLD). Long-acting bronchodilators in-
clude long-acting beta2-agonists (LABA), such as salmeterol or
formoterol, and the long-acting anticholinergic agent tiotropium.
Regular treatment with long-acting bronchodilators may be more
efficient and convenient than treatment with regular short-acting
bronchodilators (Beeh 2010). However, the Global Initiative for
Chronic Obstructive Pulmonary Disease (GOLD) guidelines do
not specify a preference between the two drug classes. For symp-
tomatic patients with severe or very severe COPD (FEV1 < 50%
predicted) and with repeated exacerbations GOLD recommends
the addition of inhaled corticosteroids (ICS) to bronchodilator
treatment. The potential risks or benefits of treatmentwith aLABA
and ICS combination inhaler compared to tiotropium are uncer-
tain (Welsh 2010), as are the risks or benefits of treatment with
a combination inhaler in addition to tiotropium, which will be
explored in this review.
How the intervention might work
Tiotropium
Tiotropium is an anticholinergic agent, blocking the action of the
neurotransmitter acetylcholine. It has an antagonistic effect on
muscarinic acetylcholine receptors. Tiotropium has similar affin-
ity for the five different subtypes of muscarinic receptors (M1
to M5), however airway smooth muscle expresses only the M2
and M3 subtypes (Proskocil 2005). Activation of the M3 recep-
tor stimulates a number of intracellular signalling cascades leading
to changes in intracellular Ca2+ homeostasis and contraction of
smooth muscle. Tiotropium dissociates slowly fromM3 receptors
giving a bronchodilator effect lasting over 24 hours, but it dis-
sociates rapidly from M2 receptors, which appear to be feedback
inhibitory receptors (Barr 2005).
Tiotropium has gained widespread acceptance for its effects on
symptoms and exacerbations as a once daily maintenance therapy
in stable COPD (Barr 2005; GOLD). In an earlier Cochrane re-
view (Barr 2005), tiotropium was shown to reduce the primary
endpoint of COPD exacerbations compared to placebo (OR 0.75;
95% CI 0.66 to 0.85). Within the same review, tiotropium was
also associated with a significant benefit over placebo measuring
breathlessness, quality of life and a reduction in exacerbations re-
quiring hospitalisation. Similar effects on symptoms and exacer-
bations were confirmed in a more recent, large randomised control
trial of almost 6000 patients followed for over four years (Tashkin
2008). There was, however, no significant effect of tiotropium on
lung function decline in this longer study. Anticholinergic side
effects that may occur with tiotropium include dry mouth, con-
stipation and tachycardia (Tashkin 2008).
Inhaled corticosteroids (ICS) and long-acting beta2-
agonist (LABA)
Inhaled beta2-agonists activate beta2-receptors in the smoothmus-
cle of the airway leading to a cascade of reactions that results in
bronchodilation. Beta2-agonists may also act through othermech-
anisms, such as respiratory muscle function or mucociliary clear-
ance, because patients have shown improvement in symptoms
whilst showing no improvement in lung function tests. Beta2-
agonists are particularly useful bronchodilators because they re-
verse bronchoconstriction regardless of the initial cause. The com-
monly used long-acting beta2 -agonists, salmeterol and formoterol,
both have a higher selectivity for beta2-receptors than beta1-recep-
tors. Beta2-receptors are the predominant adrenergic receptors in
bronchial smoothmuscle and beta1 -receptors are the predominant
receptors in the heart, although 10% to 50% of the total beta-
receptors in the heart are comprised of beta2-receptors (Wallukat
2002). The presence of beta2-receptors in the heart raises the pos-
sibility that even highly selective beta2-agonists may have cardiac
effects. The mechanism for activating beta2-receptors differs be-
tween formoterol and salmeterol. Formoterol is taken up into a
membrane depot from where it gradually leaks out to interact
with the receptor, whilst salmeterol binds near the receptor al-
lowing it to remain at the receptor site continually binding and
releasing (Johnson 1998). In both cases stimulation of the beta2-
receptors leads to changes in intracellular Ca2+ homeostasis and
bronchodilation (Tanaka 2005). The duration of action for long-
acting beta2-agonists is approximately 12 hours, and LABAs are
usually taken twice daily.
As with tiotropium, LABAs are used as ’symptom controllers’
in stable COPD. A prior Cochrane review found that LABAs
improve lung function compared to placebo (Appleton 2006).
A more recent, large (3045 patients) long-term (three year)
randomised controlled trial compared salmeterol to placebo
(TORCH) (Calverley 2007). Salmeterol use was associated with
an increase in lung function and a significant reduction in mod-
erate or severe exacerbations compared with placebo (OR 0.85, P
< 0.001). A systematic review which included the TORCH study
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and another 13 trials, with a total of 6453 participants, showed
that treatment with a LABA reduced the rate of exacerbations and
improved lung function and quality of life compared to placebo
but had no effect onmortality (Rodrigo 2008). Possible side effects
of LABAs include cardiac effects such as arrhythmia and palpita-
tions, muscle tremors, head ache and dry mouth (Berger 2008).
Inhaled corticosteroids are anti-inflammatory drugs. They reduce
the rate of exacerbations and the rate of decline in quality of life
compared to placebo without any effect on overall mortality or the
long-term decline in FEV1 (Agarwal 2010; GOLD; Yang 2007).
Inhaled corticosteroids are licensed as combination inhalers with
long-acting beta2-agonists. The most common combinations of
inhaled corticosteroid and long-acting beta2-agonist in combina-
tion inhalers are fluticasone and salmeterol and budesonide and
formoterol. Combination inhalers reduce exacerbation rates and
all-cause mortality, and improve lung function and quality of life
compared to placebo (Nannini 2007). These effects are thought
to be greater for combination inhalers than with the component
preparations (GOLD). However, inhaled corticosteroids, alone or
in combination with beta2-agonists, may increase the risk of pneu-
monia (GOLD; Singh 2010).
Why it is important to do this review
Patients with severe COPD who are symptomatic and have re-
peated exacerbations are recommended to add inhaled corticos-
teroids (ICS) to their bronchodilator treatment (LABA, anti-
cholinergic, or both), most commonly using LABA and ICS com-
bination inhalers. It is unclear what potential clinical advantages
arise by combining tiotropium with LABA and ICS compared to
tiotropiumplus LABAonly for these patients. It has been suggested
that adding combination inhaler therapy to tiotropium treatment
may be beneficial for exacerbations and hospitalisations, which are
important sources of healthcare resource utilisation and the cost
in COPD (Najafzadeh 2008). This review is necessary to specify
and quantify the potential benefits from the combination treat-
ment with LABA, ICS and tiotropium compared to LABA and
tiotropium.
This review will form part of a suite of reviews on the various
combinations of tiotropium, long-acting beta2-agonists and in-
haled corticosteroids for the treatment of COPD. These reviews
will ultimately be summarised in an overview. The first of these
reviews compared a combination of inhaled corticosteroids and
long-acting beta2-agonist with tiotropium (Welsh 2010) and fur-
ther reviews are in preparation comparing alternate permutations
of these three drugs.
O B J E C T I V E S
To compare the relative effects on measures of quality of life, ex-
acerbations, lung function and serious adverse events in patients
with chronic obstructive pulmonary disease randomised to the
following therapies:
• inhaled tiotropium, long-acting beta2-agonist and
corticosteroid versus inhaled tiotropium and long-acting beta2-
agonist.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials with a parallel
group design of at least 12 weeks duration. We did not exclude
studies on the basis of blinding.
Types of participants
We included populations with a diagnosis of chronic obstructive
pulmonary disease. We only included studies where an external
set of criteria had been used to screen participants for this condi-
tion (for example Global Initiative for Obstructive Lung Disease
(GOLD), American Thoracic Society (ATS), British Thoracic So-
ciety (BTS), The Thoracic Society of Australia and New Zealand
(TSANZ)).
Types of interventions
Inhaled corticosteroid and long-acting beta2-agonist (in either
a single combination inhaler or two separate inhalers) and
tiotropium bromide compared to inhaled long-acting beta2-ago-
nists and tiotropium administered by any inhalation device.
Types of outcome measures
Primary outcomes
1. Quality of life (measured with a validated scale for COPD,
e.g. St George’s Respiratory Questionnaire, Chronic Respiratory
Disease Questionnaire)
2. Exacerbations, requiring short burst oral corticosteroids or
antibiotic, or both
3. Pneumonia
4. Mortality, all-cause
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Secondary outcomes
1. Hospital admissions, all causes and due to exacerbations
2. Disease specific mortality, if independently adjudicated
3. Forced expiratory volume in one second (FEV1)
4. Serious adverse events, all-cause, non-fatal
5. Withdrawals
Search methods for identification of studies
Electronic searches
We identified trials using theCochrane Airways Group Specialised
Register of trials, which is derived from systematic searches of
bibliographic databases including the Cochrane Central Register
of Controlled Trials (CENTRAL) (The Cochrane Library), MED-
LINE, EMBASE, CINAHL, AMED, and PsycINFO; and hand-
searching of respiratory journals and meeting abstracts (please see
the Airways Group search methods for further details). The search
was not limited by language. All records in the Specialised Register
coded as ’COPD’ were searched using the following terms:
(tiotropium or spiriva)
AND
(((budesonide or fluticasone or beclomethasone or mometasone
or ciclesonide or steroid* or corticosteroid*) and (*formoterol or
salmeterol or indacaterol or (beta* and agonist*))) or (symbicort
or viani or seretide or advair or foster or fostair or inuvair or fostex
or kantos or combination*))
We also conducted a search of clinicaltrials.gov. The search was
carried out in February 2011.
Searching other resources
We reviewed the reference lists of the primary study and review
articles for references to other trials. We contacted authors of iden-
tified trials and manufacturers to ask them to identify other pub-
lished or unpublished studies.
Data collection and analysis
Selection of studies
Both of us screened the titles and abstracts of citations retrieved
through literature searches and obtained those deemed to be po-
tentially relevant. We assigned each reference to a study identifier
and assessed them against the inclusion criteria of this protocol.
Data extraction and management
We extracted information from the included study for the follow-
ing characteristics:
1. design (design, total duration study and run in, number of
study centres and location, withdrawals, date of study);
2. participants (N, mean age, age range, gender, COPD
severity, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, exclusion criteria);
3. interventions (run-in, intervention treatment and inhaler
type, control treatment and inhaler type);
4. outcomes (primary and secondary outcomes specified and
collected, time points reported).
Both of us extracted data from the study into a data collection
form. We discussed and resolved any discrepancies in the data, or
consulted a third party where necessary. We transferred data from
the data collection forms into Review Manager 5.
Assessment of risk of bias in included studies
We assessed the risk of bias according to recommendations out-
lined in The Cochrane Handbook for Systematic Reviews of Interve-
tions (Higgins 2011) for the following items:
1. allocation sequence generation;
2. concealment of allocation;
3. blinding of participants and investigators;
4. incomplete outcome data;
5. selective outcome reporting.
We graded each potential source of bias as low, high or unclear
risk of bias. We also planned to note other sources of bias.
Measures of treatment effect
Dichotomous data
We analysed dichotomous data variables (such as mortality and
withdrawals) using Mantel-Haenszel odds ratios using a fixed-ef-
fect model with 95% confidence intervals (CI). If events had been
rare we would have employed the Peto odds ratio since this does
not require a continuity correction for zero cells. If count data had
not been available as the number of participants experiencing an
event, we would have analysed it as continuous, time-to-event or
rate ratios depending on how it had been reported. This included
the outcomes: hospital admissions, exacerbations, and serious ad-
verse events. Reported rate ratios would have been transformed
into log rate ratios and analysed using a fixed-effect model and the
generic inverse variance (GIV) in Review Manager 5.
Continuous data
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We analysed continuous outcome data (such as FEV1 and quality
of life) as fixed-effect model mean differences (MD) with 95%
confidence intervals. If more than one study had been included
in the review, we would have analysed continuous outcome data
as fixed-effect model mean differences if the same scale had been
used, and standardised mean differences if different scales had
been employed in different studies. If treatment effects had been
reported as a mean difference with a CI or an exact P value, we
would have calculated the standard error and entered it with the
mean difference and combined the results using a fixed-effect GIV
model in Review Manager 5. If data had not been available for the
same time point in all studies, the closest time points would have
been used. The second alternative would have been to use end of
study as the time of analysis for all studies.
We planned to use intention-to-treat (ITT) analysis on outcomes,
from all randomised participants where possible, for primary anal-
yses.
We planned to calculate the numbers needed to treat from the
pooled odds ratio and its confidence interval and to apply it to
appropriate levels of baseline risk.
Unit of analysis issues
We analysed dichotomous data using participants as the unit of
analysis (rather than events) to avoid counting the same participant
more than once. For continuous data the mean difference based
on change from baseline was preferred over mean difference based
on absolute values.
Dealing with missing data
We contacted the study investigators in order to verify key study
characteristics and to obtain missing numerical outcome data
where possible. We also planned to consider the impact of the
unknown status of participants who withdrew from the trials as
part of a sensitivity analysis.
Assessment of heterogeneity
We planned to assess the amount of statistical variation between
study results with the I2 statistic.
Assessment of reporting biases
We minimised reporting bias from non-publication of studies or
selective outcome reporting by using a broad search strategy, con-
tacting study authors directly and checking references of included
studies. If we found sufficient numbers of trials, we planned to
visually inspect funnel plots.
Data synthesis
We planned to present the findings of our primary outcomes in a
summary of findings table using GradePro software and the rec-
ommendations outlined in The Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011), if there had been more
than one eligible study.
Subgroup analysis and investigation of heterogeneity
We planned to subgroup studies according to:
1. types of long-acting beta-agonist and inhaled corticosteroid;
2. severity of disease at baseline;
3. tiotropium formulation.
Sensitivity analysis
We planned to assess the sensitivity of our primary outcomes to
degree of bias by comparing the overall results with those exclu-
sively from trials assessed as being at low risk of bias.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
An initial search (July 2010) gave 101 references and additional
searches gave a further 16 references (February 2011) and nine ref-
erences (July 2011). Of the total 126 references we identified nine
as potentially relevant, which we obtained in full text for further
assessment. Five of these citations were eligible for inclusion and
they all belonged to the study Aaron 2007 (see Characteristics of
included studies).
Included studies
Aaron 2007 was a randomised, double-blind, placebo-controlled
trial with a parallel group design. The duration of the study was
one year and it was conducted in 27 different medical centres in
Canada. There were 293 participants randomised to tiotropium +
LABA and ICS (145) and tiotropium + LABA (148). The mean
age of the participants was 68 years, the mean FEV1 predicted was
39%, the gender distribution was 58% males and 42% women,
and the disease severity of the participants spanned moderate to
severe COPD according to the GOLD guideline definitions of
COPD. The participants were either given 18 µg of tiotropium
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(Handihaler) one inhalation daily plus 250 and 25 µg fluticasone
and salmeterol (Diskus) two inhalations twice daily or 18 µg of
tiotropium (Handihaler) plus 25 µg salmeterol (Diskus) two in-
halations twice daily. Participants were instructed to use inhaled
albuterol when necessary to relieve symptoms. Respiratory med-
ications such as oxygen, antileukotrienes and methylxanthines,
were continued in all patient groups. The primary outcome was
the proportion of patients suffering one or more COPD exacerba-
tions. The study was funded by the Canadian Institutes of Health
Research and the Ontario Thoracic Society.
Excluded studies
Four studies failed to meet the eligibility criteria for the review (see
Characteristics of excluded studies). All four lacked a tiotropium
plus LABA treatment group. Three of them were also of cross-
over design with a treatment period shorter than 12 weeks (Golabi
2006; Hara 2007; Mittmann 2010; Singh 2008).
Risk of bias in included studies
An assessment of the risk of bias is presented in the Characteristics
of included studies table.
Allocation
Aaron 2007 reported adequate sequence generation and allocation
concealment. Sequence generation was computer-generated and
the different inhalers were identical.
Blinding
The blinding in Aaron 2007 was adequate. Both research staff and
patients were blinded to the treatment assignment, and clinical
data for suspected exacerbations were reviewed by a blinded com-
mittee.
Incomplete outcome data
Aaron 2007 suffered from high and uneven withdrawal rates in
the different study groups (26% withdrew from the tiotropium
+ LABA and ICS group and 43% who were on tiotropium +
LABA). For most patients, data were recorded throughout the
one-year trial period regardless of whether patients discontinued
treatment with the study medications. The rate of patients who
stopped therapy and did not complete the trial, however, was still
relatively large and unevenly distributed between the intervention
groups (10% tiotropium + LABA and ICS, and 14% tiotropium
+ LABA). Mortality data were obtained for all participants with
the exception of two participants (1.4%) on tiotropium + LABA
and ICS and two (1.4%) on tiotropium + LABA who withdrew
and declined further study.
Selective reporting
Aaron 2007 adequately reported outcome data for the primary and
secondary outcomes that were pre-specified in the study record.
Effects of interventions
Data and analyses are summarised in Table 1.
Primary outcomes
Aaron 2007 (293 participants) studied changes in health-related
quality of life using the St George’s Respiratory Questionnaire
(SGRQ). A decrease in SGRQ score indicates an improvement
in quality of life and the threshold is four units for a clinically
significant difference (SGRQ-C manual 2008). At the end of the
study there was substantial uncertainty regarding the difference in
effect of tiotropium + LABA and ICS and the tiotropium + LABA
treatments on quality of life (MD -1.02; 95% CI -5.10 to 3.06).
Aaron 2007 defined COPD exacerbations as a sustained worsen-
ing of the patient’s respiratory condition necessitating short-term
use of either oral or intravenous steroids, oral or intravenous an-
tibiotics, or both therapies. There was considerable uncertainty
and no statistically significant difference in the number of patients
who had one or more exacerbations between the tiotropium +
LABA and ICS (87/145) and the tiotropium + LABA (96/148)
groups (OR 0.81; 95% CI 0.51 to 1.30).
Aaron 2007 reported one case of pneumonia (leading to mechan-
ical ventilation or death) and six deaths (all-cause) in each of
the treatment groups. There was considerable uncertainty and no
statistically significant differences between the treatment groups
(pneumonia: OR 1.02; 95% CI 0.06 to 16.48, and mortality: OR
1.02; 95% CI 0.32 to 3.24).
Secondary outcomes
Data regarding hospitalisations due to exacerbations or any cause
were kindly supplied by Aaron 2007 on request. There was no sta-
tistically significant difference in the number of patients admitted
to hospital due to exacerbation or any cause between the treat-
ment groups (all cause hospitalisation: tiotropium + LABA and
ICS 32/145, tiotropium + LABA 35/148, OR 0.91 (95% CI 0.53
to 1.58), and due to exacerbation: tiotropium + LABA and ICS
20/145, tiotropium + LABA 30/148, OR 0.63 (95% CI 0.34 to
1.17)).
Tiotropium + LABA showed no significant difference in pre-bron-
chodilator FEV1 compared to tiotropium + LABA and ICS (MD
0.07 L; 95% CI -0.03 to 0.17).
There was no statistically significant difference between
tiotropium + LABA and ICS (3/145) and tiotropium + LABA (3/
148) treatments in the number of patients suffering non-fatal seri-
ous adverse events (OR 1.02; 95%CI 0.20 to 5.14). More patients
suffered adverse events on tiotropium + LABA and ICS (44/145)
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than on tiotropium + LABA (32/148) (OR 1.58; 95% CI 0.93 to
2.68), although the difference was not statistically significant.
The number of withdrawals from Aaron 2007 for any reason
was high and the withdrawal rate was significantly higher in the
tiotropium + LABA group (43%) than in the tiotropium + LABA
and ICS group (26%) (OR 0.45; 95% CI 0.27 to 0.74). Aaron
2007 reported the breakdown of the reasons for withdrawing from
the study treatment, which included: adverse event, declined fur-
ther study, lost to follow up, or lack of efficacy. Lack of efficacy was
the sum of patients withdrawn from the study treatment because
of treatment failure according to physician and patient perceptions
of worsening of COPD. The difference between the number with-
drawing due to adverse events (OR 1.38; 95% CI 0.47 to 4.09)
was not statistically significant, whereas the difference between the
number withdrawing due to lack of efficacywas significantly lower
in the tiotropium + LABA and ICS group (25/145) than in the
tiotropium + LABA group (54/148) (OR 0.36; 95% CI 0.21 to
0.63).
D I S C U S S I O N
This systematic review set out to investigate the long-term (≥ three
month) effect of tiotropium in combination with LABA and ICS
compared to tiotropium + LABA for the treatment of COPD.
One randomised, double-blind trial with 293 participants was
identified. The Aaron 2007 study was of good methodological
quality, however it suffered fromhigh and unevenwithdrawal rates
between the treatment arms. The data from Aaron 2007 showed
considerable uncertainty and no statistically significant difference
between patients treated with tiotropium + LABA and ICS, and
tiotropium + LABA for the outcomes: health-related quality of
life, exacerbations, pneumonia, mortality, hospitalisations, FEV1
and adverse events. The fact that only one, relatively small study
was included in this review and that is suffered large and uneven
withdrawals makes the results for outcomes with few events or
small differences less reliable. However, the statistically significant
difference in the number of patients who withdrew due to lack
of efficacy may imply some beneficial effect of ICS and LABA +
tiotropium compared to LABA + tiotropium treatment. Around
75% of participants in both treatment groups received ICS or ICS
and LABA combination therapy before entering the trial (Aaron
2007). If the participants who were on ICS treatment at the time
of randomisation represents ICS responders, this could lead to
greater drop-outs in the placebo arm when these patients noticed
a lack of benefit.
Several systematic reviews have tried to investigate the contri-
bution of ICS to the benefits and risks of combination thera-
pies in COPD. Systematic reviews comparing ICS treatment with
placebo and LABA and ICS combination treatment to LABA
alone have shown that ICS reduces the occurrence of exacerba-
tions (Agarwal 2010; Nannini 2007a; Rodrigo 2009) and has pos-
itive effects on quality of life and lung function (Nannini 2007a;
Rodrigo 2009; Yang 2007). ICS treatment on its own or in com-
bination with LABA has not been shown to have any significant
effect on mortality (Nannini 2007a; Rodrigo 2009; Yang 2007).
However, pneumonia occurs more frequently with ICS treatment
and the elevated risk remained consistent irrespective of whether
LABA and ICS combination inhalers were compared to LABA,
ICS or to placebo (Nannini 2007a; Rodrigo 2009; Singh 2010).
The potential effect of ICS on medical expenses for COPD pa-
tients has also been evaluated. Compared to placebo, ICS reduces
costs and improves outcomes in patients aged over 50 years, al-
though estimated cost saving per avoided exacerbation is uncer-
tain (Akazawa 2008). The cost effectiveness of LABA and ICS
combination therapy compared to LABA monotherapy seems to
favour combination therapy based on a significant gain in quality-
adjusted life years (Briggs 2010) and potentially an overall savings
in total COPD-related exacerbation and therapeutic healthcare
costs (Dalal 2010).
In summary, because of the limited evidence presented in this
review, It is unclear if adding ICS to tiotropium + LABA will lead
to similar clinical improvements, risks and cost effectiveness as
when added to LABA monotherapy or placebo.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There was only a single study conducted with few patients and
therefore there are insufficient data to draw any conclusions re-
garding the long-term effects and risks of tiotropium + LABA and
ICS treatment compared to tiotropium + LABA. The relative ef-
ficacy and safety of adding ICS to tiotropium + LABA therefore
remain uncertain.
Implications for research
Additional large, long-term randomised controlled trials are re-
quired to show any potential benefits and risks of taking LABA
and ICS combination inhaler together with tiotropium rather than
only tiotropium and LABA for COPD patients.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aaron 2007
Methods Design: A randomised, double-blind, placebo-controlled, parallel group trial from Oc-
tober 2003 to January 2006. The trial included 27 Canadian medical centres; 20 centres
were academic hospital-based pulmonary clinics, 5 were community-based pulmonary
clinics, and 2 were community-based primary care clinics
Participants Population: 293 adults with a clinical history of moderate or severe COPD as defined
by ATS and GOLD guidelines
Baseline Characteristics: Mean age 68 years. COPD severity moderate to severe with
mean FEV1 predicted of 39%. 58% men.
Inclusion Criteria: At least 1 exacerbation of COPD that required treatment with
systemic steroids or antibiotics within the 12 months before randomisation; age older
than 35 years; a history of 10 pack-years or more of cigarette smoking; documented
chronic airflow obstruction, with an FEV1/FVC ratio < 0.70 and a post-bronchodilator
FEV1 < 65% of the predicted value.
Exclusion Criteria: History of physician-diagnosed asthma before 40 years of age; his-
tory of physician-diagnosed chronic congestive heart failure with known persistent severe
left ventricular dysfunction; those receiving oral prednisone; those with a known hy-
persensitivity or intolerance to tiotropium, salmeterol, or fluticasone-salmeterol; history
of severe glaucoma or severe urinary tract obstruction, previous lung transplantation or
lung volume reduction surgery, or diffuse bilateral bronchiectasis; and those who were
pregnant or were breastfeeding
Interventions 1. Tiotropium + salmeterol + fluticasone: tiotropium (Spiriva, Handihaler (Boehringer
Ingelheim Pharma, Ingelheim, Germany)), 18 g once daily, plus fluticasone-salmeterol
(Advair (GlaxoSmithKline)), 250/25 g/puff, 2 puffs twice daily
2. Tiotropium + salmeterol: tiotropium, 18 g once daily, plus salmeterol (Serevent (Glax-
oSmithKline, Research Triangle Park, North Carolina)), 25 g/puff, 2 puffs twice daily
Outcomes Primary: Proportion of patients with one or more exacerbation of COPD
Secondary: Mean number of COPD exacerbations per patient-year; the total number of
exacerbations that resulted in urgent visits to a healthcare provider or emergency depart-
ment; the number of hospitalisations for COPD; the total number of hospitalisations
for all causes; changes in health-related quality of life, dyspnoea, lung function
Notes Co-medication: All study patients were provided with inhaled albuterol and were in-
structed to use it when necessary to relieve symptoms. Any treatment with inhaled cor-
ticosteroids, long-acting beta2-agonists, and anticholinergics that the patient may have
been using before entry was discontinued on entry into the study. Therapy with other
respiratorymedications, such as oxygen, antileukotrienes, andmethylxanthines, was con-
tinued in all patient groups
Risk of bias
Bias Authors’ judgement Support for judgement
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Aaron 2007 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation was done through central
allocation of a randomisation schedule that
was prepared from a computer-generated
random listing of the 3 treatment alloca-
tions, blocked in variable blocks of 9 or 12
and stratified by site
Allocation concealment (selection bias) Low risk The metered-dose inhalers containing
placebo, salmeterol, and fluticasone-salme-
terol were identical in taste and appear-
ance, and they were enclosed in identical
tamper-proof blinding devices. The medi-
cation canisters within the blinding devices
were stripped of any identifying labelling
Blinding (performance bias and detection
bias)
All outcomes
Low risk Neither research staff nor patients were
aware of the treatment assignment before
or after randomisation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The number of people who stopped
drug therapy was high, with large varia-
tions between the groups (37/145 (26%)
tiotropium + LABA/ICS and 64/148
(43%) tiotropium + LABA). However, the
number of people who did not complete
the trial was lower, although there was still
some variations between the groups (15
(10%) tiotropium + LABA/ICS and 20
(14%) tiotropium + LABA). The issue of
incomplete data was however addressed by
sensitivity analyses of the data for the pri-
mary outcome (exacerbations). In the pri-
mary analysis it was assumed that all pa-
tients who were lost to follow-up did not
have an exacerbation (ITT analysis). In the
sensitivity analyses it was assumed that pa-
tients who were lost to follow-up either all
had an exacerbation or had exacerbations
at the same rate as those who continued in
the study. Both analyses gave a similar re-
sult to the primary ITT analysis
Selective reporting (reporting bias) Low risk Results for all listed primary and secondary
outcomes were reported
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Golabi 2006 Four weeks of treatment, only tiotropium alone and salmeterol/fluticasone treatment groups, cross-over design
Hara 2007 Eight weeks of treatment, only tiotropium alone and salmeterol/fluticasone treatment groups, cross-over design
Mittmann 2010 No tiotropium plus LABA treatment group
Singh 2008 Two weeks of treatment, no tiotropium plus LABA treatment group, and of cross-over design
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Data analysis summary
Outcome Effect estimate
Quality of life (SGRQ) MD -1.02; 95% CI -5.10 to 3.06
Number of patients with ≥1 exacerbations OR 0.81; 95% CI 0.51 to 1.30
Number of patients suffering from pneumonia OR 1.02; 95% CI 0.06 to 16.48
Mortality OR 1.02; 95% CI 0.32 to 3.24
Number of patients with ≥1 hospitalisations (all cause) OR 0.91; 95% CI 0.53 to 1.58
Number of patients with≥1 hospitalisations due to exacerbations OR 0.63; 95% CI 0.34 to 1.17
Pre-dose FEV1 MD 0.07; 95% CI -0.03 to 0.17
Number of patients suffering≥1 serious adverse events (non-fatal) OR 1.02; 95% CI 0.20 to 5.14
Number of patients suffering ≥1 adverse events OR 1.58; 95% CI 0.93 to 2.68
Total number of patients withdrawn OR 0.45; 95% CI 0.27 to 0.74
Number of patients withdrawn due to adverse events OR 1.38; 95% CI 0.47 to 4.09
Number of patients withdrawn due to lack of efficacy OR 0.36; 95% CI 0.21 to 0.63
H I S T O R Y
Protocol first published: Issue 3, 2011
Review first published: Issue 9, 2011
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